MCT1 is a new prognostic biomarker and its therapeutic inhibition boosts response to temozolomide in human glioblastoma

<i>Background:</i> Glioblastomas (GBMs) present remarkable metabolism reprograming, in which many cells display the “Warburg effect”, with the production of high levels of lactate that are extruded to the tumour microenvironment by monocarboxylate transporters (MCTs). We described previo...

ver descrição completa

Detalhes bibliográficos
Autor principal: Miranda-Gonçalves, Vera (author)
Outros Autores: Gonçalves, Celine Saraiva (author), Granja, Sara Costa (author), Castro, Joana Isabel Martins Cosme Vieira (author), Reis, Rui M. (author), Costa, Bruno M. (author), Baltazar, Fátima (author)
Formato: article
Idioma:eng
Publicado em: 2021
Assuntos:
Monocarboxylate transporters
Glioblastoma
Lactate
Warburg effect
Prognostic biomarker
Science & Technology
Texto completo:http://hdl.handle.net/1822/74346
País:Portugal
Oai:oai:repositorium.sdum.uminho.pt:1822/74346

Texto Completo

http://hdl.handle.net/1822/74346

Registos relacionados